Researchers at University of California San Diego School of Medicine discovered that they can block inflammation in mice with a naturally occurring antibody that binds oxidized phospholipids (OxPL), molecules on cell surfaces that get modified by inflammation. Even while on a high-fat diet, the antibody protected the mice from arterial plaque formation, hardening of the arteries and liver disease, and prolonged their lives.
This study, published June 6 by Nature, marks the first demonstration in a living system that OxPL triggers inflammation and leads to plaque formation. The results also suggest a new approach for preventing or reversing a number of inflammatory diseases.
“Wherever you get inflammation, you get OxPL,” said senior author Joseph Witztum, MD, professor of medicine at UC San Diego School of Medicine. “It doesn’t mean OxPL is the cause, but it definitely plays a major role.” Witztum led the study with first author Xuchu Que, PhD, a senior project scientist at UC San Diego School of Medicine.
Some phospholipids — the molecules that make up cell membranes — are prone to modification by reactive oxygen species, forming OxPL. This event is particularly common in inflammatory conditions such as atherosclerosis, in which artery-blocking plaques form. Prior to this study, researchers were unable to control phospholipid oxidation in a way that would allow them to study its role in inflammation and atherosclerosis.
Witztum, Que and team engineered mice with two special attributes: 1) they have a gene mutation that makes them a good model for atherosclerosis and 2) they generate a piece of an antibody called E06 that’s just enough to bind OxPL and prevent their ability to cause inflammation in immune cells, but not enough to cause inflammation on its own. They fed the mice a high-fat diet.
Here’s what happened: Compared to control mice, the mice with E06 antibodies had 28 to 57 percent less atherosclerosis, even after one year and despite having high levels of cholesterol. The antibody also decreased aortic valve calcification (hardening and narrowing of the aortic valves), hepatic steatosis (fatty liver disease) and liver inflammation. E06 antibody-producing mice had 32 percent less serum amyloid A, a marker of systemic inflammation.
The E06 antibody also prolonged the life of the mice. After 15 months, all of the E06 antibody-producing mice were alive, compared to 54 percent of the control mice.
“We showed for the first time that OxPL are truly pro-inflammatory and pro-atherogenic and, moreover, that they can be counteracted by E06 antibody,” Witztum said. “This suggests that therapies that inactivate OxPL may be beneficial for reducing inflammation in general, and in particular in the case of diseases such as atherosclerosis, aortic stenosis and hepatic steatosis.”
Witztum and team are now testing E06 antibody in mouse models of human diseases linked to inflammation, such as osteoporosis (bone loss) and nonalcoholic steatohepatitis (NASH, a type of liver disease).
The Latest on: Inflammation
via Google News
The Latest on: Inflammation
- In Vivo Probes for Detecting Inflammation Markers in Humans and Animalson February 24, 2021 at 8:19 am
News-Medical talks to Parry Hashemi about research on in vivo probes for detecting inflammation markers in humans and animals she will present at Pittcon.
- The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPOon February 24, 2021 at 4:30 am
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 23) AxoGen, Inc ...
- MicroRNA-17-3p suppresses NF-κB-mediated endothelial inflammation by targeting NIK and IKKβ binding proteinon February 23, 2021 at 10:24 am
The present study tested the hypothesis that microRNA-17-3p (miR-17-3p) suppresses the pro-inflammatory responses via NF-κB signaling in vascular endothelium. Human umbilical vein endothelial cells ...
- OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammationon February 22, 2021 at 11:00 pm
OKYO Pharma Limited, a biotechnology company focused on the development of novel drugs to treat inflammatory eye diseases and chronic ocular pain, today announced that patent No. 10,899,796 entitled“ ...
- Fructose reprogrammes glutamine-dependent oxidative metabolism to support LPS-induced inflammationon February 22, 2021 at 4:56 am
Myeloid cells are able to utilize a variety of monosaccharides from our diet, including fructose. Here the authors show that when monocytes are reliant on fructose as a carbon energy source they are ...
- Chronic Inflammation: When too much of a good thing turns deadlyon February 21, 2021 at 1:39 pm
“Chronic inflammatory diseases are the most significant cause of death in the world. The World Health Organization ranks chronic diseases as the greatest threat to human health.” ...
- 2021 Pipeline Insights on the Inflammation and Pain Post Cataract Surgery Industry - ResearchAndMarkets.comon February 19, 2021 at 7:10 am
Pipeline Insights on the Inflammation and Pain Post Cataract Surgery Industry - ResearchAndMarkets.com The “Inflammation and Pain Post Cataract Surgery - Pipeline Insight, 2021” drug pipelines has ...
- Linden Botanicals Releases Free Inflammation Support E-Bookon February 18, 2021 at 10:39 pm
The new e-book includes strategies for reducing inflammation, which can signal overactive immune response or diabetes, heart disease, Crohn’s disease, or lupus.
- If Inflammation Causes Obesity, Can Cannabis Help Break The Vicious Cycle?on February 18, 2021 at 10:36 am
The Fresh Toast - Many chronic related conditions are in one way or another related to inflammation. Obesity is no exception to this trend. - Medical Marijuana ...
via Bing News